“A vote of confidence in British business,” trumpeted Andy Burnham, seizing the political gift of GSK splashing out £400m on a shiny new research and development centre in Cambridge.
For positive vibes, it definitely beats the early pharma news his predecessor as prime minister received. That was the painful tale of how AstraZeneca, frustrated by indecision in the Treasury, cancelled its intended £450m expansion of a vaccine plant in Speke in Liverpool.
